Beyond BRCA: Exploring PARP Combinations in Prostate Cancer

Download All
Hear from the experts on how the latest clinical data from ASCO GU 2021 inform leveraging PARP inhibitor–based combinations for treating prostate cancer with and without DNA damage repair alterations. Review their insights in clinical commentaries along with slides, a podcast, and on-demand Webcast adapted from a live CCO Webinar.
Charles J. Ryan, MD
Neal D. Shore, MD, FACS

On-Demand Webcast

Learn about the many ongoing clinical trials for prostate cancer leveraging PARP inhibitors combined with a variety of agents including AR-directed therapy, immunotherapy, and other targeted agents.

Charles J. Ryan, MD Neal D. Shore, MD, FACS Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s) Released: March 30, 2021 Expired: March 29, 2022
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.
Pfizer

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue